global
matern
infant
mortal
remain
unaccept
high
centuri
despit
reduct
sinc
global
matern
mortal
ratio
estim
per
live
birth
matern
death
per
day
mostli
associ
pregnanc
childbirth
complic
occur
develop
world
similarli
million
children
year
age
die
nearli
everi
day
neonat
mortal
account
approxim
death
world
health
organ
therefor
includ
sustain
develop
goal
sdg
target
goal
reduc
global
matern
mortal
ratio
per
live
birth
end
prevent
death
newborn
children
year
age
aim
countri
reduc
neonat
mortal
per
live
birth
mortal
per
live
birth
achiev
target
intervent
address
promin
caus
mortal
target
group
requir
expans
enhanc
integr
matern
earli
life
immun
key
public
health
intervent
potenti
address
goal
pregnant
women
infant
high
risk
exposur
infecti
diseas
vaccin
administ
pregnanc
andor
earli
life
offer
potenti
protect
depend
vaccin
mother
infectionrel
morbid
mortal
infant
infectionrel
morbid
neonat
death
stillbirth
preterm
birth
feasibl
matern
immun
support
success
longstand
matern
neonat
tetanu
elimin
mnte
program
given
grow
number
vaccin
recommend
use
pregnanc
ie
influenza
pertussi
new
matern
vaccin
develop
ie
respiratori
syncyti
viru
rsv
group
b
streptococcu
gb
critic
understand
challeng
opportun
implement
matern
immun
area
vulner
popul
would
benefit
includ
low
middleincom
countri
lmic
leverag
exist
antenat
care
anc
program
expert
bill
melinda
gate
foundat
bmgf
conven
meet
matern
immun
resourcelimit
set
agre
matern
immun
must
integr
within
anc
platform
approach
support
strateg
advisori
group
expert
immun
sage
advis
world
health
organ
gener
generaliz
data
best
way
integr
matern
immun
routin
antenat
care
lowresourc
set
sever
global
project
address
mandat
identifi
opportun
challeng
introduct
new
vaccin
matern
immun
matern
influenza
immun
project
provid
guidelin
implement
influenza
vaccin
pregnant
women
lmic
matern
immun
antenat
care
situat
analysi
miacsa
aim
evalu
tetanu
matern
vaccin
deliveri
via
exist
anc
program
identifi
opportun
challeng
introduct
new
vaccin
matern
immun
vaccin
specif
develop
matern
immun
includ
vaccin
gb
lead
etiolog
agent
neonat
sepsi
neonat
mening
plu
substanti
matern
morbiditymort
pregnanc
postpartum
rsv
vaccin
order
prevent
substanti
morbid
mortal
caus
rsv
young
infant
similarli
path
advanc
matern
immun
ami
collabor
collabor
evalu
rsv
implement
matern
vaccin
particularli
lmic
http
sitespathorgcviaourdiseasetargetsrespiratorysyncytialvirusadvancingmaternalimmunizationami
product
develop
vaccin
advisori
committe
pdvac
identifi
prioriti
develop
gb
vaccin
suitabl
matern
immun
pregnanc
use
lmic
respons
develop
gb
prefer
product
characterist
ppc
guidelin
vaccin
develop
technolog
roadmap
focu
activ
lead
develop
test
licensur
global
avail
gb
vaccin
document
avail
http
wwwwhointimmunizationresearchdevelopmentppcgroupbstrepvaccinesen
april
sage
acknowledg
high
import
rsv
vaccin
develop
prevent
pediatr
morbid
mortal
sinc
rsv
vaccin
advanc
phase
clinic
trial
pregnant
women
inform
vaccin
develop
licensur
prequalif
develop
guidanc
rsv
vaccin
efficaci
trial
design
prevent
acut
diseas
focu
lmic
rsv
vaccin
technolog
roadmap
rsv
vaccin
prefer
product
characterist
ppc
document
guid
vaccin
develop
evalu
found
http
wwwwhointimmunizationresearchdevelopmentppcrsvvaccinesen
regulatori
physic
standard
rsv
vaccin
apprais
data
relev
rsv
vaccin
polici
vaccin
use
guidanc
longterm
vaccin
evalu
includ
document
intern
neonat
matern
immun
symposium
inmi
conven
expert
academia
industri
regulatori
fund
agenc
public
health
intern
organ
brussel
belgium
septemb
review
relev
advanc
matern
neonat
immun
overarch
focu
confer
identifi
path
forward
achiev
integr
matern
earli
life
immun
strategi
success
implement
vaccin
antenat
care
harmon
vaccin
matern
neonat
health
care
program
impact
matern
infant
mortal
worldwid
nearli
particip
attend
twoandahalfday
meet
includ
invit
expert
present
oral
present
submit
abstract
poster
present
expert
panel
discuss
meet
session
organ
begin
day
gener
topic
immunolog
includ
understand
antibodi
transfer
mother
infant
neonat
immun
heterolog
immun
second
day
dedic
provid
updat
vaccin
develop
matern
neonat
immun
address
also
safeti
awar
percept
issu
final
third
day
focus
implement
aspect
matern
neonat
immun
worldwid
futur
direct
includ
new
futur
target
matern
neonat
immun
antibodi
transfer
introduct
develop
new
vaccin
margaret
ackerman
dartmouth
colleg
usa
discuss
vaccin
design
inform
system
serolog
approach
pursu
collabor
galit
alter
ragon
institut
cambridg
usa
use
hiv
infect
hiv
vaccin
exampl
dr
ackerman
illustr
machinelearn
tool
employ
learn
principl
effect
antibodi
ab
respons
human
subject
specif
neutral
activ
antibodi
ab
depend
fab
fragment
antigen
bind
domain
wherea
fc
fragment
crystal
domain
mediat
effector
function
interact
innat
immun
cell
complement
import
interact
illustr
reduc
efficaci
hiv
broadli
neutral
antibodi
mutat
prevent
interact
fc
receptor
effector
function
mediat
igg
fc
domain
diversifi
differ
igg
subclass
posttransl
modif
primarili
involv
glycosyl
import
fc
glycosyl
illustr
impact
matern
antiplatelet
igg
fucosyl
sever
fetal
thrombocytopenia
gain
insight
rule
govern
vaccin
efficaci
ab
respons
two
hiv
vaccin
formul
base
antigen
versu
compar
larg
rang
featur
assess
broadli
character
ab
identifi
correl
protect
structur
ab
featur
could
link
receptor
bind
function
properti
could
correl
vaccin
efficaci
observ
support
notion
system
serolog
could
inform
vaccin
design
divers
popul
includ
pregnant
women
infant
dana
wolf
hadassah
univers
hospit
israel
discuss
congenit
infect
provid
insight
placent
biolog
transfer
matern
immun
placenta
play
central
role
matern
toler
fetu
activ
transport
matern
igg
via
neonat
fc
receptor
express
syncytiotrophoblast
placenta
also
innat
immun
barrier
pathogen
syncytiotrophoblast
known
resist
infect
multipl
pathogen
thought
fetal
infect
may
involv
transplacent
transport
complex
form
pathogen
matern
antibodi
hand
infect
decidua
form
matern
compon
placenta
like
initi
pathogen
transmiss
fetu
dr
wolf
present
develop
ex
vivo
model
infect
decidua
cultur
allow
character
pathogen
spread
innat
immun
respons
model
demonstr
cytomegaloviru
cmv
spread
cell
cell
wherea
zika
viru
zikv
spread
via
extracellular
space
gene
express
analys
reveal
cmv
zikv
induc
distinct
placent
respons
may
underli
distinct
mechan
viral
control
tissu
damag
indepth
analysi
gene
express
indic
intrins
cellular
restrict
factor
may
import
innat
mechan
cmv
control
placent
level
work
help
develop
intervent
protect
placent
function
prevent
pathogen
transmiss
follow
matern
infect
thao
mai
phuong
tran
univers
hasselt
belgium
discuss
mathemat
model
matern
antibodi
titer
infant
matern
immun
belgium
vietnam
differ
brand
pertussiscontain
vaccin
differ
matern
antibodi
kinet
similar
halfliv
note
young
infant
countri
concentr
birth
lower
infant
vietnam
infant
belgium
futur
research
assess
impact
time
matern
vaccin
differ
stage
gestat
antibodi
concentr
infant
birth
refin
model
mustapha
jaiteh
medic
research
council
unit
gambia
mrcg
london
school
tropic
medicin
lshtm
present
preliminari
result
suggest
impact
matern
vaccin
pneumococc
conjug
vaccin
presenc
vaccin
antigenspecif
memori
b
cell
colostrum
potenti
mechan
underli
neonat
protect
via
matern
immun
breast
milk
antibodi
ii
neonat
immun
despit
challeng
inher
vaccin
develop
young
robust
rational
continu
vaccin
develop
popul
includ
birth
reliabl
point
health
care
contact
therefor
neonat
vaccin
achiev
high
popul
penetr
b
neonat
immun
logic
approach
protect
preterm
infant
repres
live
birth
often
born
prior
transfer
matern
antibodi
matab
matern
immun
may
protect
c
grow
evid
heterolog
benefit
certain
vaccin
bcg
may
greatest
earli
life
beat
kampmann
imperi
colleg
london
mrcg
lshtm
gambia
challeng
view
newborn
respond
well
vaccin
emphas
import
consid
differ
newborn
vaccin
immun
ontogeni
earli
life
shape
innat
adapt
respons
influenc
matern
cofactor
immun
plastic
requir
integr
genet
environment
factor
adapt
ex
utero
environ
immun
compon
central
vaccin
respons
includ
antigenpres
cell
b
cell
cell
function
differ
birth
later
life
matern
cofactor
influenc
immun
ontogeni
immun
respons
earli
life
includ
chronic
matern
infect
nutrit
microbiom
level
specif
matern
acquir
antibodi
vaccin
current
given
birth
provid
strong
evid
protect
immun
induc
vaccin
also
inform
potenti
neonat
develop
specif
immun
respons
impact
cofactor
studi
bcg
immun
demonstr
respons
induc
birth
bcg
vaccin
heterolog
effect
respons
vaccin
overal
infant
mortal
studi
hepat
b
oral
polio
immun
birth
indic
prime
memori
b
cell
achiev
earli
life
allow
option
immun
infant
birth
ideal
vaccin
administ
neonat
would
induc
rapid
immun
respons
even
presenc
matab
would
optim
safeti
profil
nichola
wood
univers
sydney
australia
discuss
role
neonat
immun
protect
bacteri
pathogen
includ
pertussi
haemophilu
influenza
type
b
hib
pneumococcu
major
death
due
whoop
cough
occur
first
two
month
life
pertussi
vaccin
earli
life
result
variabl
outcom
histor
studi
suggest
immun
toler
may
result
neonat
pertussi
immun
wholecel
vaccin
recent
studi
show
acellular
pertussi
vaccin
birth
increas
respons
second
dose
vaccin
month
life
prime
role
studi
show
reduc
respons
vaccin
concomitantli
administ
second
pertussi
vaccin
dose
anoth
limit
pertussi
immun
birth
may
induct
cellular
immun
respons
neonat
pertussi
immun
may
indic
babi
born
mother
low
ab
level
reduc
respons
pertussi
vaccin
reduc
transfer
matab
public
health
point
view
feasibl
indic
question
sever
studi
neonat
hib
immun
show
good
safeti
prime
booster
respons
polyribosylribitol
phosphatediphtheria
crm
protein
prpcrm
prptetanu
protein
prpt
vaccin
reduc
booster
respons
prpouter
membran
protein
prpomp
vaccin
studi
neonat
immun
pneumococc
conjug
vaccin
show
good
safeti
earli
induct
ab
impact
invas
diseas
carriag
yet
demonstr
merryn
voysey
univers
oxford
unit
kingdom
discuss
preval
decay
matab
differ
pneumococc
meningococc
vaccin
trial
show
differ
serotyp
serogroup
countri
presenc
matab
result
interfer
activ
infant
immun
data
use
model
impact
program
util
combin
matern
infant
vaccin
strategi
ofer
levi
precis
vaccin
program
boston
children
hospit
harvard
medic
school
usa
present
preliminari
vitro
studi
employ
human
wholeblood
assay
rais
possibl
bcg
formul
heterogen
may
contribut
variabl
clinic
benefit
includ
offtarget
heterolog
protect
highlight
need
standard
compar
differ
bcg
vaccin
optim
benefit
data
present
ed
clark
mrcg
lshtm
gambia
show
vaccinespecif
memori
b
cell
respons
pneumococcu
antigen
detect
mother
infant
matern
immun
pneumococc
vaccin
gaell
noel
univers
maryland
school
medicin
usa
present
data
demonstr
breast
milk
enhanc
intestin
mucos
barrier
pediatr
human
enteroid
model
john
ojal
kemriwellcom
trust
research
program
data
indic
natur
acquir
matab
pneumococc
protein
protect
infant
carriag
wherea
vaccineinduc
antipolysaccharid
ab
may
requir
concentr
higher
induc
natur
immun
effect
iii
heterolog
immun
mihai
netea
radboud
univers
netherland
review
concept
innat
immun
memori
heterolog
effect
vaccin
highlight
upon
introduct
bcg
vaccin
sweden
infant
mortal
drop
manner
could
account
sole
prevent
tuberculosi
subsequ
random
studi
lowbirthweight
newborn
guinea
bissau
demonstr
newborn
receiv
bcg
birth
versu
month
reduct
mortal
sever
investig
hypothes
mechan
underli
rapid
bcg
effect
may
relat
innat
immun
evolutionari
perspect
may
seem
logic
vertebr
repres
known
organ
would
reli
adapt
respons
immunolog
memori
moreov
broad
system
acquir
resist
pathogen
well
describ
plant
transmit
next
gener
via
epigenet
mechan
innat
memori
also
exist
mammal
less
well
studi
exampl
mice
lack
b
lymphocyt
myeloid
cell
provid
protect
follow
vaccin
candida
protect
also
involv
epigenet
mechan
key
histon
modif
increas
access
chromatin
detect
prime
monocyt
block
modif
inhibit
cell
prime
epigenet
modif
relat
metabol
chang
includ
chang
kreb
cycl
also
demonstr
human
adult
follow
bcg
vaccin
relev
antimicrobi
defens
support
recent
data
indic
decreas
viral
replic
subject
receiv
bcg
yellow
fever
vaccin
overal
evid
innat
immun
respons
chang
adapt
manner
infect
vaccin
carlo
pietrasanta
boston
children
hospit
harvard
medic
school
usa
report
certain
combin
stimul
interferon
gene
sting
tolllik
receptor
tlr
agonist
act
synergi
activ
respons
human
neonat
antigenpres
cell
suggest
sting
agonist
alon
combin
alum
andor
tlr
agonist
may
candid
adjuv
earli
life
immun
selena
alonso
barcelona
institut
global
health
spain
discuss
impact
matern
infect
infant
respons
vaccin
present
result
studi
conduct
mozambiqu
indic
alter
immun
respons
vaccin
antigen
hib
rotaviru
pertussi
diphtheria
infant
born
mother
infect
hiv
malaria
unexpectedli
intrapartum
prophylaxi
mefloquin
neg
impact
vaccin
respons
jishnu
da
ragon
institut
usa
describ
studi
conduct
belgium
show
hivexpos
uninfect
infant
higher
risk
hospit
infect
variou
etiolog
unexpos
infant
risk
hospit
relat
time
initi
antiretrovir
therapi
pregnant
women
predict
immun
alter
measur
birth
risk
hospit
higher
mother
initi
therapi
pregnanc
significantli
increas
treatment
start
pregnanc
rsv
immun
pregnanc
fiona
culley
imperi
colleg
london
unit
kingdom
remind
audienc
rsv
lead
singl
caus
hospit
infant
worldwid
signific
caus
global
death
especi
lmic
adult
repeatedli
infect
rsv
strain
natur
immun
may
partial
effect
natur
serum
ab
associ
protect
although
nasal
rsvspecif
iga
may
provid
better
correl
best
evid
protect
come
success
monoclon
antibodi
mab
f
protein
hand
age
profil
rsv
diseas
support
associ
suscept
level
matab
one
model
studi
show
everi
doubl
ab
vaccin
sever
diseas
may
reduc
protect
prolong
addit
day
matern
immun
attract
option
number
vaccin
candid
develop
evalu
factor
import
consid
candid
vaccin
includ
much
ab
gener
mother
variabl
respons
best
gestat
age
vaccin
protect
mother
placent
transfer
ab
impact
breast
feed
persist
presenc
passiv
acquir
ab
possibl
interfer
infant
respons
natur
infect
potenti
effect
delay
age
infect
later
childhood
addit
strategi
consid
includ
cocoon
use
pediatr
rsv
vaccin
extendedhalflif
mab
formul
ii
gb
immun
pregnanc
group
b
streptococcu
lead
caus
matern
neonat
morbid
worldwid
recent
estim
associ
gb
least
uncertainti
rang
ur
maternalfetalinf
case
diseas
ur
stillbirth
infant
death
annual
anticip
effect
vaccin
could
substanti
reduc
burden
gb
diseas
shabir
madhi
univers
witwatersrand
south
africa
emphas
gb
diseas
underrecogn
global
caus
death
disabl
especi
lmic
part
current
tool
measur
suboptim
previou
estim
show
virtual
absenc
gb
southeast
asia
observ
contrast
substanti
matern
colon
rate
set
underdetect
invas
infect
may
due
fact
earlyonset
diseas
occur
day
life
bulk
diseas
attribut
infant
mortal
unrecogn
case
die
home
investig
adequ
health
care
facil
due
resourc
constraint
even
highincom
countri
effect
use
intrapartum
antibiot
remain
residu
burden
earlyonset
diseas
intrapartum
prophylaxi
impact
lateonset
diseas
sinc
histor
observ
lower
level
anticapsular
ab
correl
invas
diseas
work
defin
threshold
associ
protect
progress
limit
use
differ
unstandard
assay
recent
studi
conjug
vaccin
demonstr
safeti
immunogen
good
persist
ab
vaccin
mother
variat
preexist
natur
immun
comorbid
ethnic
good
placent
transfer
ab
persist
infant
also
observ
longterm
persist
matab
may
less
import
gb
infect
rsv
highest
burden
gb
mortal
first
week
life
coverag
first
month
life
matern
vaccin
suffici
address
earli
lateonset
diseas
hiv
infect
import
risk
factor
infant
gb
diseas
lower
respons
candid
gb
vaccin
seen
hivinfect
uninfect
women
dr
madhi
refer
two
recent
public
describ
pathway
develop
prefer
product
characterist
gb
vaccin
manu
chaudhari
baylor
colleg
medicin
usa
share
result
studi
conduct
unit
state
gb
colon
preval
women
india
indian
descent
live
unit
state
compar
gener
unit
state
higher
india
gb
colon
preval
higher
women
indian
descent
born
unit
state
born
india
isol
gb
type
reflect
countri
includ
type
vii
preval
south
asia
type
iv
emerg
unit
state
iii
pertussi
immun
pregnanc
kathryn
edward
vanderbilt
univers
school
medicin
usa
gave
overview
histor
perspect
rational
maternalfet
antibodi
transfer
effect
safeti
matern
immun
pertussi
discuss
impact
matern
antibodi
matab
infant
immun
respons
pertussiscontain
vaccin
evid
robust
matern
immun
acellular
pertussi
vaccin
safe
effect
protect
neonat
young
infant
diseas
line
increas
bodi
evid
support
safeti
immunogen
protect
efficaci
tdap
pregnanc
studi
evalu
optim
time
vaccin
pregnanc
indic
vaccin
second
earli
third
trimest
might
result
higher
neonat
ab
concentr
impact
matab
modifi
infant
immun
respons
howev
one
remain
challeng
tdap
vaccin
pregnanc
research
final
theoret
concern
interfer
crmconjug
vaccin
respons
infant
shown
recent
studi
nasamon
wanlapakorn
chulalongkorn
univers
thailand
present
result
ongo
studi
thailand
infant
born
tdapvaccin
women
random
either
wholecel
pertussi
acellular
pertussiscontain
infant
vaccin
optim
time
tdap
vaccin
pregnanc
calcul
least
week
prior
deliveri
ratio
maternalcord
vaccineinduc
ab
higher
tdap
vaccin
offer
earlier
pregnanc
result
infant
respons
yet
avail
thoma
rice
imperi
colleg
london
unit
kingdom
report
matimm
studi
imperi
colleg
unit
kingdom
investig
contribut
emerg
pertussi
strain
earli
cellular
immun
respons
vaccin
use
wholeblood
stimul
assay
elev
cellular
immun
respons
vaccin
women
suggest
vaccin
pregnanc
also
boost
cellular
respons
women
straindepend
respons
evid
significantli
higher
ab
titer
present
vaccin
women
persist
offspr
infant
vaccin
start
apcontain
infant
vaccin
cytokin
respons
strain
depend
differ
cytokin
infant
carolina
argondizo
adolfo
lutz
institut
brazil
also
report
cellular
immun
respons
pattern
mother
infant
use
flow
cytometri
tdap
pregnanc
enhanc
antipt
cellular
immun
respons
women
confirm
boost
cellular
immun
adult
age
dose
wpcontain
vaccin
given
infant
infant
cellular
immun
respons
differ
studi
group
born
vaccin
unvaccin
women
despit
blunt
effect
matab
infant
born
vaccin
women
discuss
question
rais
whether
abovement
studi
captur
vaccin
nonspecif
heterolog
effect
matern
immun
requir
assess
nonspecif
featur
studi
design
well
larger
studi
popul
broader
document
diseas
morbid
mortal
summari
thorough
review
exist
evid
matern
tdap
vaccin
benefit
remain
knowledg
gap
studi
result
thailand
brazil
unit
kingdom
could
answer
one
remain
question
impact
matern
vaccin
cellular
immun
respons
women
infant
safeti
awar
percept
matern
neonat
immun
next
session
dedic
examin
percept
relat
matern
immun
global
might
impact
vaccin
uptak
global
effort
way
strengthen
harmon
safeti
monitor
area
percept
risk
relat
matern
neonat
immun
import
build
trust
heidi
larson
london
school
hygien
tropic
medicin
unit
kingdom
open
session
provid
insight
issu
relat
vaccin
accept
highlight
univers
sensit
natur
pregnanc
worldwid
irrespect
cultur
fact
anxieti
relat
mani
vaccin
focus
perceiv
effect
fertil
reproduct
hpv
vaccin
particular
exampl
fact
health
belief
model
incorpor
individu
understand
risk
diseas
accept
intervent
repres
oversimplif
emot
determin
health
also
need
includ
also
discuss
dr
larson
highlight
trust
product
ie
vaccin
provid
polici
polici
maker
requir
effect
vaccin
deliveri
uptak
like
compromis
compon
lack
also
drew
attent
fact
vaccin
target
diseas
newborn
eg
pertussi
might
accept
differ
predominantli
target
matern
diseas
eg
influenza
final
dr
larson
describ
effort
vaccin
confid
project
http
wwwvaccineconfidenceorg
establish
estim
regard
popul
view
import
safeti
effect
compat
religi
belief
outlin
mani
local
contextu
factor
influenc
estim
ii
assess
safeti
linda
eckert
univers
washington
seattl
wa
usa
describ
effort
harmon
assess
safeti
vaccin
pregnanc
provid
perspect
frontlin
obstetrician
first
highlight
safeti
repres
key
obstacl
matern
immun
effici
use
data
studi
outcom
requir
agreement
regard
term
definit
use
dr
eckert
describ
global
align
immun
safeti
assess
pregnanc
gaia
consortium
base
brighton
collabor
recent
publish
definit
obstetr
neonat
use
safeti
report
matern
immun
http
gaiaconsortiumnet
crown
initi
set
journal
editor
establish
core
outcom
set
report
obstetr
neonat
studi
also
describ
http
wwwcrowninitiativeorg
set
preterm
birth
core
outcom
recent
publish
group
outcom
follow
number
ongo
initi
describ
dr
eckert
conclud
pois
new
era
harmon
safeti
report
field
matern
neonat
vaccin
clare
cutland
univers
witwatersrand
south
africa
provid
perspect
lmic
assess
safeti
efficaci
matern
vaccin
consid
immun
data
collect
routin
health
care
facil
south
africa
gambia
ghana
india
nepal
highlight
collect
safeti
data
clinic
trial
routin
follow
implement
would
present
differ
challeng
paperbas
patientheld
immun
record
current
use
countri
field
recod
essenti
data
includ
vaccin
lot
number
manufactur
volum
site
immun
lack
reliabl
electr
suppli
computertablet
hardwar
avail
mani
lmic
limit
electron
data
captur
clinic
set
south
africa
creativ
solut
use
differ
size
local
coin
allow
evalu
consist
measur
size
local
vaccin
reaction
util
major
lmic
pregnanc
record
maintain
paper
card
taken
home
mother
postdeliveri
system
central
storag
antenat
data
place
hamper
assess
background
rate
matern
fetal
newborn
advers
event
make
retrospect
studi
nearli
imposs
number
step
could
taken
enhanc
safeti
report
lmic
describ
ensur
futur
introduct
vaccin
need
delay
ousseni
zerbo
kaiser
permanent
vaccin
studi
center
usa
present
data
gener
kaiser
permanent
site
northern
california
demonstr
abil
conduct
power
analys
use
extens
data
deliveri
studi
confirm
absenc
associ
matern
influenza
vaccin
differ
advers
birth
outcom
includ
preterm
birth
low
birth
weight
larg
small
size
gestat
age
penda
johm
mrcg
lshtm
gambia
discuss
qualit
data
gener
context
matern
vaccin
trial
gambia
report
matern
neonat
dose
vaccin
perceiv
safe
studi
particip
although
appar
variabl
level
understand
regard
ill
vaccin
may
prevent
potenti
barrier
futur
uptak
identifi
focu
studi
undertaken
gambia
seneg
outsid
site
alreadi
undertak
vaccin
trial
order
elimin
bia
steve
anderson
food
drug
administr
unit
state
describ
work
us
food
drug
administr
fda
develop
capabl
monitor
safeti
vaccin
use
pregnanc
sentinel
initi
postlicensur
rapid
immun
safeti
monitor
prism
program
http
blogsfdagovfdavoiceindexphptagsentinelin
activ
surveil
system
analyz
inform
electron
health
care
databas
philip
lambach
initi
vaccin
research
provid
global
perspect
opportun
challeng
matern
immun
particular
focu
lesson
learn
influenza
vaccin
introduct
highlight
gap
implement
research
need
optim
deliveri
strategi
vaccin
pregnanc
import
place
support
research
highlight
strateg
advisori
group
expert
sage
progress
challeng
opportun
matern
influenza
immun
identifi
region
describ
african
region
afro
compet
infecti
diseas
prioriti
signific
concern
low
popul
uptak
european
region
euro
particular
challeng
current
panamerican
health
organ
paho
report
region
make
strongest
progress
overal
dr
lambach
describ
framework
introduc
new
matern
vaccin
countri
program
start
decis
polici
maker
move
role
undertak
implement
plan
introduct
undertak
train
ensur
effect
commun
subsequ
monitor
evalu
program
final
matern
influenza
introduct
implement
manual
fittingli
launch
day
meet
septemb
recommend
audienc
sourc
extend
program
immun
epi
manag
interest
parti
plan
introduct
guidanc
document
found
http
edwin
asturia
univers
colorado
denver
co
usa
discuss
fact
integr
matern
young
infant
immun
program
must
address
effect
schedul
safeti
immunogen
overal
efficaci
vaccin
well
programmat
issu
ideal
schedul
consid
offer
best
opportun
provid
optim
protect
minimum
risk
highlight
primari
immun
schedul
adopt
maxim
vaccin
coverag
earli
infanc
rapidli
possibl
highli
effect
prevent
diseas
howev
realiti
infant
receiv
vaccin
averag
month
age
mani
factor
affect
infant
respons
primari
seri
list
dr
asturia
review
number
key
public
demonstr
effect
matab
includ
breast
milk
ab
infant
vaccin
immunogen
also
highlight
grow
appreci
role
microbiota
infant
immun
conclud
true
integr
matern
infant
immun
schedul
might
involv
delay
administr
vaccin
antigen
infant
effect
protect
matab
ab
wane
suffici
would
also
provid
greater
opportun
later
booster
vaccin
requir
longterm
protect
mani
case
indirect
protect
popul
martinez
de
tejada
univers
hospit
geneva
switzerland
present
result
two
prospect
observ
nonrandom
studi
compar
transfer
antipertussi
ab
newborn
follow
vaccin
second
compar
third
trimest
pregnanc
term
preterm
infant
secondtrimest
vaccin
confer
higher
ab
concentr
newborn
henc
lower
number
infant
remain
seroneg
follow
secondtrimest
vaccin
dr
martinez
de
tejada
conclud
recommend
secondtrimest
pertussi
vaccin
gayatri
amirthalingam
public
health
england
unit
kingdom
discuss
success
challeng
matern
pertussi
immun
program
england
program
introduc
respons
sharp
increas
pertussi
diseas
case
young
vaccin
although
program
success
implement
earli
coverag
increas
start
window
vaccin
broaden
week
gestat
base
data
recent
studi
describ
previou
present
vaccin
effect
demonstr
consist
sinc
introduct
unit
kingdom
infant
mortal
pertussi
substanti
decreas
sinc
introduct
matern
tdap
vaccin
case
death
report
date
infant
born
correctli
vaccin
mother
dr
amirthalingam
also
highlight
effect
matern
antibodi
matab
infant
immun
respons
thu
far
translat
measur
impact
clinic
diseas
young
children
sonali
kochhar
global
healthcar
consult
india
provid
overview
studi
design
regulatori
safeti
consider
matern
immun
clinic
research
low
middleincom
countri
beat
kampmann
imperi
colleg
london
unit
kingdom
introduc
recent
form
immun
pregnant
women
infant
imprint
network
highlight
purpos
network
bring
togeth
multidisciplinari
stakehold
field
address
specif
scientif
challeng
http
wwwimprintnetworkcouk
monoclon
antibodi
jame
crow
vanderbilt
univers
nashvil
tn
usa
suggest
next
year
ab
new
tool
prevent
infecti
diseas
ration
structurebas
vaccin
design
replac
empir
antigen
develop
better
understand
share
element
human
immun
system
key
understand
perform
vaccin
ab
although
human
genom
differ
contend
ab
gene
much
ab
produc
studi
one
person
respons
gener
other
ab
technolog
matur
rapid
afford
experi
safeti
ab
administr
conceptu
much
less
complex
vaccin
current
licens
prophylact
ab
anthrax
rsv
pipelin
includ
nextgener
rsv
clostridium
difficil
pseudomona
aeruginosa
staphylococc
toxin
influenza
viru
ab
first
success
identif
therapeut
ab
marburg
viru
ongo
studi
hemorrhag
fever
zikv
potenti
new
target
includ
pandem
influenza
elderli
infant
season
influenza
zikv
gb
pertussi
mrsa
nosocomi
infect
eg
acinetobact
sp
other
current
list
agent
concern
eg
rift
valley
fever
viru
lassa
fever
viru
pan
flaviviru
mer
cov
therapeut
rabi
viru
structurebas
vaccin
anoth
option
develop
new
vaccin
new
epitop
altern
way
identifi
new
candid
instead
whole
infecti
agent
human
immunom
project
http
wwwhumanvaccinesprojectorgworkhumanimmunomeprogram
aim
determin
sequenc
everi
human
ab
cell
receptor
human
immunom
compris
complet
set
recombin
immun
receptor
b
cell
receptor
gene
much
larger
human
genom
goal
human
immunom
project
defin
number
sequenc
stabil
repertoir
time
proport
share
immunom
effect
age
raceethn
gender
geographi
effect
vaccin
diseas
immunom
defin
complet
structur
function
catalogu
project
allow
investig
better
profil
respons
vaccin
understand
genet
featur
underli
variabl
respons
facilit
ration
structurebas
design
identifi
new
abbas
therapeut
ii
vaccin
malaria
enter
pathogen
sophi
roetynk
mrcg
lshtm
gambia
present
promis
result
random
control
trial
safeti
immunogen
malaria
adenovirusvector
vaccin
metrap
infant
neonat
vaccin
safe
well
toler
result
highlevel
immunogen
highest
peak
respons
observ
infant
vaccin
week
age
interfer
epi
vaccin
esther
ndungo
univers
maryland
school
medicin
usa
show
result
studi
evalu
infant
protect
shigellosi
natur
acquir
vaccineinduc
matern
immun
mous
model
shigella
primari
caus
diarrhea
children
year
age
accord
find
global
enter
multicent
studi
gem
mous
model
matern
antibodi
matab
transfer
challeng
studi
dr
ndungo
demonstr
shigella
antigenspecif
igg
function
ab
transfer
pup
via
placenta
milk
immun
mother
matern
vaccin
system
igg
protect
infant
mice
mucos
infect
protect
persist
beyond
wean
seroepidemiolog
cohort
studi
maternalinf
pair
conduct
malawi
evalu
presenc
invas
plasmid
antigen
b
ipab
lipopolysaccharid
lp
specif
ab
mother
transplacent
transfer
newborn
durat
infant
correl
protect
iii
prevent
multidrug
resist
antibiot
ajok
sobanjot
meulen
bmgf
usa
emphas
global
neonat
mortal
rate
declin
slowli
childhood
mortal
rate
also
note
grow
number
facilitybas
birth
especi
india
signific
implic
health
careassoci
neonat
infect
show
data
delhi
neonat
infect
studi
deni
collabor
hospit
delhi
high
antimicrobi
resist
rate
among
neonat
pathogen
especi
gramneg
bacteria
countri
highest
mortal
rate
also
demonstr
higher
sepsi
death
rate
well
higher
prematur
intrapartum
stillbirth
rate
outcom
may
reflect
underli
infect
evid
support
hypothesi
exist
champ
studi
http
champshealthorg
recent
review
estim
burden
global
death
due
sepsi
antimicrobialresist
amr
organ
matern
vaccin
especi
rsv
gb
potenti
reduc
amr
reduc
empir
use
antibiot
regard
gb
strain
mention
rise
rate
resist
secondlin
antibiot
macrolid
tetracyclin
note
larg
number
women
highincom
countri
receiv
antibiot
labor
order
prevent
earlyonset
gb
diseas
thu
effect
vaccin
could
potenti
reduc
number
infect
reduc
need
antibiot
reduc
emerg
resist
strain
improv
prevent
resist
strain
theoret
vaccin
could
use
target
determin
antibiot
resist
vaccin
import
gramneg
pathogen
alreadi
horizon
develop
monoclon
antibodi
mab
birth
also
part
bill
melinda
gate
foundat
strategi
wherea
prophylact
mab
could
given
infant
determin
risk
mab
may
reduc
need
durat
antibiot
approach
could
potenti
combin
matern
immun
pathogen
discuss
panel
discuss
meet
conclud
two
panel
discuss
first
panel
focus
topic
implement
integr
matern
infant
immun
challeng
opportun
particip
ask
address
follow
key
question
key
challeng
implement
matern
immun
program
worldwid
feasibl
key
challeng
integr
matern
infant
immun
schedul
critic
knowledg
gap
need
address
order
ensur
success
implement
matern
immun
program
complement
infant
immun
program
base
expertis
potenti
solut
challeng
knowledg
gap
identifi
outcom
panel
describ
tabl
addit
panel
ask
consid
feasibl
integr
matern
infant
immun
schedul
respons
principl
feasibl
mani
countri
take
consider
success
maternalneonat
tetanu
program
order
achiev
panel
suggest
follow
develop
matern
immun
invest
case
depict
concept
advantag
matern
immun
use
matern
tetanu
vaccin
exampl
commonli
appreci
lmic
substanti
sound
countryspecif
evid
diseas
burdenidentif
champion
push
matern
immun
agenda
especi
region
countri
levelpromot
function
integr
epi
matern
neonat
child
health
mnch
program
use
avail
mean
nation
govern
drive
process
ideal
equip
anc
clinic
immun
skillsa
strong
matern
immun
platform
requir
normal
vaccin
practic
among
obstetr
care
provid
support
basic
continu
educ
commun
strategi
broad
rang
researchresourc
requir
implic
includ
human
resourc
fund
adequ
assess
made
avail
earli
time
avail
resourc
program
implement
commun
awar
instrumentalinvolv
profession
associ
obstetrician
gynecologist
public
health
physician
ongo
sensitizationadvocaci
capac
build
manufactur
health
care
provid
explicit
provid
safeti
inform
specif
relat
product
use
pregnanc
neonat
second
panel
discuss
focus
identifi
key
messag
stakehold
panel
member
chosen
repres
multipl
disciplin
relev
field
panelist
prepar
statement
summar
key
challeng
area
propos
solut
summar
tabl
basic
scienc
evolv
quickli
provid
new
insight
mechan
protect
mother
young
infant
matern
immun
clear
challeng
goal
formul
particip
meet
span
basic
scienc
clinic
research
implement
work
progress
area
need
enhanc
knowledg
vaccin
current
recommend
matern
neonat
immun
neonat
immun
develop
deriv
ration
futur
target
vaccin
pregnanc
earli
life
meet
deliber
activ
contribut
toward
goal
global
implement
integr
matern
infant
vaccin
strategi
